ArticleDiscover oncology2026
A new cuproptosis-associated lncRNA signature predicts the prognosis of clear cell renal cell carcinoma patients.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveClear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma. Cuproptosis is a new type of programmed cell death that is mediated by protein lipid acylation and is closely linked to mitochondrial metabolism.
methodsThe Cancer Genome Atlas (TCGA) database provided us with RNA-Seq data together with the related clinical and prognostic information. Using univariate Cox, 135 prognostic lncRNAs associated with cuproptosis were identified for use in prognostic model construction. Multivariate Cox analysis was subsequently used to further integrate these lncRNAs. We used subject operating characteristic (ROC) curve analysis and Kaplan-Meier (K-M) survival curve analysis to assess the model’s prognostic ability. In order to predict immune escape and potential therapeutic drugs in the two groups, we also looked at the differences in immunological and tumor mutational burden between the high- and low-risk groups. The quantitative polymerase chain reaction (Q-PCR) was then used to validate the risk model.
resultsThe lncRNA profile linked to cuproptosis is used to divide patients into two risk categories, with the lower risk group having a better prognosis. The tumor mutational burden was larger, immune escape was more likely to occur, and immunotherapy results were generally worse in the high-risk group. The traditional chemotherapeutic medications sunitinib, AKT inhibitor VIII, rapamycin, and lapatinib were more effective in low-risk individuals. Six prognostic lncRNAs were ultimately confirmed in human cell lines, including HK-2, ACHN, 769-P, and CAKI-1.
conclusionsA risk model based on six cuproptosis-related lncRNAs has a high predictive value for ccRCC and might be a medical target for cuproptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.